{"id":"aripezil-tab","_chembl":null,"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Aripezil® Tab.","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T05:06:43.119064+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T05:06:58.917559+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T05:06:50.101514+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Aripezil® Tab.","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T05:06:50.731499+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4542707/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T05:06:51.355785+00:00"}},"_dailymed":null,"aiSummary":"Aripezil® Tablet, marketed by Yuhan Corporation, holds a position in the pharmaceutical market with its key composition patent set to expire in 2028. The drug's primary strength lies in its current market presence, leveraging its established patient base and brand recognition. The primary risk is the potential increase in competition post-patent expiry, which could erode market share and revenue.","_scrapedAt":"2026-03-27T23:42:35.713Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T05:06:58.918111+00:00","fieldsConflicting":0,"overallConfidence":0.95},"trialDetails":[{"nctId":"NCT03441516","phase":"PHASE4","title":"Effect of Choline Alphoscerate on Cognitive Function in Alzheimer's Dementia","status":"UNKNOWN","sponsor":"Yuhan Corporation","startDate":"2018-04-19","conditions":"Alzheimer's Disease","enrollment":79}],"_emaApprovals":[],"_faersSignals":[],"crossReferences":{"chemblId":"CHEMBL4542707"},"_approvalHistory":[],"publicationCount":5885,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Aripezil® Tab.","genericName":"Aripezil® Tab.","companyName":"Yuhan Corporation","companyId":"yuhan-corporation","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T05:06:58.918111+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}